Загрузка...
Hydroxyurea therapy for sickle cell anemia
INTRODUCTION: Sickle cell anemia (SCA) is a severe, inherited hemoglobin disorder affecting 100,000 persons in the US and millions worldwide. Hydroxyurea, a once daily oral medication, has emerged as the primary disease-modifying therapy for SCA. The accumulated body of evidence over 30 years demons...
Сохранить в:
| Опубликовано в: : | Expert Opin Drug Saf |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5868345/ https://ncbi.nlm.nih.gov/pubmed/26366626 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14740338.2015.1088827 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|